<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04015687</url>
  </required_header>
  <id_info>
    <org_study_id>AG881-C-006</org_study_id>
    <nct_id>NCT04015687</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults</brief_title>
  <official_title>A Phase 1, Open-label Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agios Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agios Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to examine the effect of multiple doses of AG-881 on the&#xD;
      pharmacokinetics (PK) of a single dose of lamotrigine in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Actual">October 9, 2019</completion_date>
  <primary_completion_date type="Actual">October 9, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the Concentration-time Curve from Time 0 to Infinity (AUC0-inf) for Lamotrigine Administered with Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Concentration-time Curve from Time 0 to Infinity (AUC0-inf) for Lamotrigine Administered without Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for Lamotrigine Administered with Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for Lamotrigine Administered without Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Concentration-time Curve, from Time 0 to the Last Observed Non-zero Concentration (t) (AUC0-t) for Lamotrigine Administered with Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Concentration-time Curve, from Time 0 to the Last Observed Non-zero Concentration (t) (AUC0-t) for Lamotrigine Administered without Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of AUC0-inf Extrapolated (AUC%extrap) for Lamotrigine Administered with Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of AUC0-inf Extrapolated (AUC%extrap) for Lamotrigine Administered without Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) for Lamotrigine Administered with Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) for Lamotrigine Administered without Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Rate Constant (Kel) for Lamotrigine Administered with Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Rate Constant (Kel) for Lamotrigine Administered without Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Half-life (t½) for Lamotrigine Administered with Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Half-life (t½) for Lamotrigine Administered without Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Plasma Clearance after Oral (Extravascular) Administration (CL/F) for Lamotrigine Administered with Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Plasma Clearance after Oral (Extravascular) Administration (CL/F) for Lamotrigine Administered without Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution during the Terminal Elimination Phase after Oral (Extravascular) Administration (Vz/F) for Lamotrigine Administered with Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution during the Terminal Elimination Phase after Oral (Extravascular) Administration (Vz/F) for Lamotrigine Administered without Interacting Drug AG-881</measure>
    <time_frame>At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
    <description>An AE is any untoward medical occurrence associated with the use of a drug, whether or not considered drug-related.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia-suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
    <description>The C-SSRS is a questionnaire scale to detect emergent suicide symptoms (suicidal ideation or actual suicidal behavior). Questions are either answered yes/no or are on a scale of 1 (low severity) to 5 (high severity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in 12-lead Electrocardiograms (ECGs)</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in Vital Sign Measurements</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
    <description>Vital signs will include body temperature, respiratory rate, blood pressure, and heart rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in Clinical Laboratory Tests</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
    <description>Clinical laboratory assessments will include hematology, serum chemistry, coagulation, and urinalysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in Physical Examinations</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>AG-881 (Group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of Period 1, Group 1 participants will receive a single 50-milligram (mg) oral dose of lamotrigine at Hour 0. In Period 2, they will receive 50-mg oral doses of AG-881 once daily (QD) for 15 consecutive days (Days 1 to 15), with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AG-881 (Group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following a safety and tolerability review of the data from at least 7 days of AG-881 dosing of Group 1 participants in Period 2, Group 2 participants will receive a single 50-mg oral dose of lamotrigine at Hour 0 in Period 1, and 50-mg oral doses of AG-881 QD for 15 consecutive days (Days 1 to 15), with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14 in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AG-881 (Group 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following a safety and tolerability review of the data from Group 1 participants, and from at least 7 days of AG-881 dosing of Group 2 participants in Period 2, Group 3 participants will receive a single 50-mg oral dose of lamotrigine at Hour 0 in Period 1; and 50-mg oral doses of AG-881 QD for 15 consecutive days (Days 1 to 15) with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14 in Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AG-881</intervention_name>
    <description>Supplied as uncoated tablets.</description>
    <arm_group_label>AG-881 (Group 1)</arm_group_label>
    <arm_group_label>AG-881 (Group 2)</arm_group_label>
    <arm_group_label>AG-881 (Group 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>Supplied as tablets of LAMICTAL® or generic equivalent.</description>
    <arm_group_label>AG-881 (Group 1)</arm_group_label>
    <arm_group_label>AG-881 (Group 2)</arm_group_label>
    <arm_group_label>AG-881 (Group 3)</arm_group_label>
    <other_name>LAMICTAL®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Healthy, adult, male or female participants, 18-55 years of age, inclusive, at&#xD;
             screening;&#xD;
&#xD;
          -  Continuous non-smoker who has not used nicotine-containing products for at least 3&#xD;
             months prior to the first dosing and throughout the study, based on participant&#xD;
             self-reporting;&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kilograms per square meter (kg/m^2) at&#xD;
             screening;&#xD;
&#xD;
          -  Medically healthy with no clinically significant medical history, physical&#xD;
             examination, laboratory profiles, vital signs or electrocardiograms (ECG), as deemed&#xD;
             by the principal investigator or designee;&#xD;
&#xD;
          -  Liver function tests (serum alanine aminotransferase [ALT], aspartate aminotransferase&#xD;
             [AST], alkaline phosphatase [ALP], and bilirubin [total and direct]) must be ≤ the&#xD;
             upper limit of normal;&#xD;
&#xD;
          -  Female participants must be of non-childbearing potential defined as a female who has&#xD;
             undergone one of the following sterilization procedures at least 6 months prior to the&#xD;
             first dosing:&#xD;
&#xD;
               -  hysteroscopic sterilization;&#xD;
&#xD;
               -  bilateral tubal ligation or bilateral salpingectomy;&#xD;
&#xD;
               -  hysterectomy;&#xD;
&#xD;
               -  bilateral oophorectomy;&#xD;
&#xD;
               -  or is postmenopausal with amenorrhea for at least 1 year prior to the first&#xD;
                  dosing and follicle-stimulating hormone (FSH) serum levels consistent with&#xD;
                  postmenopausal status;&#xD;
&#xD;
          -  A non-vasectomized, male participant must agree to use a condom with spermicide or&#xD;
             abstain from sexual intercourse during the study until 90 days after the last dosing.&#xD;
             (No restrictions are required for a vasectomized male provided his vasectomy has been&#xD;
             performed 4 months or more prior to the first dosing of study drug. A male who has&#xD;
             been vasectomized less than 4 months prior to study first dosing must follow the same&#xD;
             restrictions as a non-vasectomized male);&#xD;
&#xD;
          -  If a male participant, must agree not to donate sperm from the first dosing until 90&#xD;
             days after the last dosing;&#xD;
&#xD;
          -  Understands the study procedures in the informed consent form (ICF), and be willing&#xD;
             and able to comply with the protocol.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Participant is mentally or legally incapacitated or has significant emotional problems&#xD;
             at the time of the screening visit or expected during the conduct of the study;&#xD;
&#xD;
          -  History or presence of clinically significant medical or psychiatric condition or&#xD;
             disease in the opinion of the principal investigator or designee;&#xD;
&#xD;
          -  History of any illness that, in the opinion of the principal investigator or designee,&#xD;
             might confound the results of the study or pose an additional risk to the participant&#xD;
             (e.g., history or presence of rashes) by their participation in the study;&#xD;
&#xD;
          -  History or presence of ventricular dysfunction or risk factors for Torsades de Pointes&#xD;
             (e.g., heart failure, hypokalemia, cardiomyopathy, family history of Long QT&#xD;
             Syndrome), in the opinion of the principal investigator or designee;&#xD;
&#xD;
          -  History or presence of alcoholism or drug abuse within the past 2 years prior to the&#xD;
             first dosing;&#xD;
&#xD;
          -  History or presence of hypersensitivity or idiosyncratic reaction to the study drugs&#xD;
             or related compounds;&#xD;
&#xD;
          -  Known medical history of progressive multifocal leukoencephalopathy;&#xD;
&#xD;
          -  Presence of an active skin rash;&#xD;
&#xD;
          -  Any positive responses on the Columbia-suicide severity rating scale (C-SSRS);&#xD;
&#xD;
          -  Female participants of childbearing potential;&#xD;
&#xD;
          -  Female participants with a positive pregnancy test or who are lactating;&#xD;
&#xD;
          -  Positive urine drug or alcohol results at screening or first check-in;&#xD;
&#xD;
          -  Positive results at screening for human immunodeficiency virus (HIV) antibodies,&#xD;
             hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies;&#xD;
&#xD;
          -  Corrected QT interval by Fridericia (QTcF) is &gt;450 milliseconds (msec), or Q wave, R&#xD;
             wave, and S wave complex (QRS) interval &gt;110 msec, or P wave to the start of the QRS&#xD;
             complex (PR interval) &gt;220 msec or participants who have ECG findings deemed abnormal&#xD;
             with clinical significance by the principal investigator or designee at screening;&#xD;
&#xD;
          -  Estimated creatinine clearance &lt;90 millimeters per minute (mL/min) at screening;&#xD;
&#xD;
          -  Unable to refrain from or anticipate the use of:&#xD;
&#xD;
               -  Any drug, including prescription and non-prescription medications, herbal&#xD;
                  remedies, and vitamin supplements, beginning 14 days prior to the first dosing&#xD;
                  and throughout the study. After first dosing, ibuprofen (1.2 grams [g] per 24&#xD;
                  hours) may be administered at the discretion of principal investigator or&#xD;
                  designee;&#xD;
&#xD;
               -  Any drugs known to be strong inducers of cytochrome P450 (CYP) 3A enzymes or&#xD;
                  uridine 5´-diphospho-glucuronyl transferases (UGTs), including St. John's Wort,&#xD;
                  for 28 days prior to the first dosing and throughout the study. Appropriate&#xD;
                  sources (e.g., Flockhart Table™) will be consulted to confirm lack of&#xD;
                  pharmacokinetic/pharmacodynamic interaction with study drug;&#xD;
&#xD;
          -  Refuses to abstain from grapefruit-containing foods or beverages or Seville orange&#xD;
             containing foods or beverages from 14 days prior to the first dosing and throughout&#xD;
             the study;&#xD;
&#xD;
          -  Has been on a diet incompatible with the on-study diet, in the opinion of the&#xD;
             principal investigator or designee, within the 30 days prior to the first dosing and&#xD;
             throughout the study;&#xD;
&#xD;
          -  Donation of blood or significant blood loss within 56 days prior to the first dose;&#xD;
&#xD;
          -  Plasma donation within 7 days prior to the first dose;&#xD;
&#xD;
          -  Participation in another clinical study within 30 days prior to the first dose. The&#xD;
             30-day window will be derived from the date of the last blood collection or dosing,&#xD;
             whichever is later, in the previous study to Day 1 of the current study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Affairs</last_name>
    <role>Study Director</role>
    <affiliation>Agios Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion, Inc</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2019</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

